Last reviewed · How we verify

oxybutynin IR

Allergan · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

oxybutynin IR is a Small molecule drug developed by Allergan. It is currently FDA-approved. Also known as: Ditropan.

Oxybutynin IR is a small molecule that acts as a muscarinic acetylcholine receptor M3 antagonist. It is used to treat conditions such as overactive bladder and neurogenic detrusor overactivity, particularly in individuals with spinal cord injuries.

At a glance

Generic nameoxybutynin IR
Also known asDitropan
SponsorAllergan
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about oxybutynin IR

What is oxybutynin IR?

oxybutynin IR is a Small molecule drug developed by Allergan.

Who makes oxybutynin IR?

oxybutynin IR is developed and marketed by Allergan (see full Allergan pipeline at /company/allergan).

Is oxybutynin IR also known as anything else?

oxybutynin IR is also known as Ditropan.

What development phase is oxybutynin IR in?

oxybutynin IR is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing